This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

A Biotech Stock Without the Risk

Stocks in this article: BRLI

ELMWOOD PARK, N.J. ( TheStreet) -- Bio-Reference Laboratories (BRLI) sounds like a high-flying biotech stock that trades on the hopes the company will discover a cure for cancer.

Bio-Reference, in reality, is boring, making it worthy of an investment. It's certainly no Antigenics (AGEN), Dendreon (DNDN) or InterMune (ITMN).

Based in Elmwood Park, N.J., Bio-Reference operates an independent clinical laboratory that specializes in genomics, oncology, correctional health and complementary medicine. The company draws revenue from conducting tests for physicians' offices and handling clinical testing. It avoids much of the uncertainty in biotechnology by simply extracting a fee for testing services without being tied to the success or failure of those tests.

Staying Healthy In Big Cities (Forbes)

At its essence, Bio-Reference is really just a service provider, despite being lumped into the volatile health-care sector. The company's relative safety can be seen in its low beta value of only 0.86, indicating the stock doesn't offer much non-diversifiable risk, making it a solid holding for most portfolios.

Bio-Reference has gained 86% over the past year versus 25% for the S&P 500 Index. Dendreon, one of the hottest biotech stocks, has risen 99%. But it also has sky-high volatility.

Bio-Reference has tamed its borrowing during the past three years, making it even safer. The debt-to-equity ratio has fallen from 0.42 in the year ending October 2007 to just 0.2 for the year ending October 2009. This judicious use of debt financing has led to a rock-solid balance sheet that sports a current ratio of 2.2 as of January 2010.

While the lack of leverage may have hampered returns, a return on equity of 19.3% for fiscal 2009 beat the industry average of 12.6%. In sum, Bio-Reference is more stable and more profitable than others in the industry.

Value investors, however, may be turned off. A PEG ratio (a measure of price-to-growth prospects) of 1.4 and a price-to-free-cash-flow ratio of 40.5 are high, and a price-to-earnings ratio of 20 is expensive compared with the industry average of 15.

Bio-Reference is clearly a growth stock. Analysts predict earnings will grow 20% this year and 14% in 2011, and revenue will rise 17% and 19%.

Bio-Reference carries a grade of A from TheStreet's ratings model with a "buy" recommendation. The stock is in the top 20 in terms of overall score.

More on Biotech
14 Biotech Stocks Facing FDA Approval

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs